aflibercept
E238303
Aflibercept is an anti-VEGF biologic drug used primarily to treat neovascular (wet) age-related macular degeneration and other retinal vascular diseases.
All labels observed (1)
| Label | Occurrences |
|---|---|
| aflibercept canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T2138580 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: aflibercept Context triple: [Lucentis, isRelatedDrug, aflibercept]
-
A.
Lucentis
Lucentis is a prescription anti-VEGF biologic drug used to treat several serious eye diseases, including wet age-related macular degeneration and diabetic macular edema, by inhibiting abnormal blood vessel growth in the retina.
-
B.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
C.
faricimab
Faricimab is a bispecific monoclonal antibody used to treat neovascular eye diseases such as wet age-related macular degeneration and diabetic macular edema by targeting both VEGF-A and Ang-2 pathways.
-
D.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
E.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: aflibercept Target entity description: Aflibercept is an anti-VEGF biologic drug used primarily to treat neovascular (wet) age-related macular degeneration and other retinal vascular diseases.
-
A.
Lucentis
Lucentis is a prescription anti-VEGF biologic drug used to treat several serious eye diseases, including wet age-related macular degeneration and diabetic macular edema, by inhibiting abnormal blood vessel growth in the retina.
-
B.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
C.
faricimab
Faricimab is a bispecific monoclonal antibody used to treat neovascular eye diseases such as wet age-related macular degeneration and diabetic macular edema by targeting both VEGF-A and Ang-2 pathways.
-
D.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
E.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
- F. None of above. chosen
Statements (58)
| Predicate | Object |
|---|---|
| instanceOf |
angiogenesis inhibitor
ⓘ
anti-VEGF agent ⓘ biologic drug ⓘ ophthalmic drug ⓘ recombinant fusion protein ⓘ |
| administrationFrequency |
every 4 weeks (loading phase, intravitreal)
ⓘ
every 8 weeks (maintenance phase, intravitreal) ⓘ |
| coDeveloper |
Bayer
ⓘ
surface form:
Bayer HealthCare
|
| commonAdverseEffect |
cataract
ⓘ
conjunctival hemorrhage ⓘ eye pain ⓘ increased intraocular pressure ⓘ |
| contains |
Fc portion of human IgG1
ⓘ
extracellular domains of VEGFR-1 ⓘ extracellular domains of VEGFR-2 ⓘ |
| contraindication |
active severe intraocular inflammation
ⓘ
ocular or periocular infection ⓘ |
| developer | Regeneron Pharmaceuticals ⓘ |
| hasATCCode |
L01XX44
ⓘ
S01LA05 ⓘ |
| hasTradeName |
Eylea
ⓘ
Zaltrap ⓘ |
| indication |
branch retinal vein occlusion
ⓘ
central retinal vein occlusion ⓘ diabetic macular edema ⓘ macular edema following retinal vein occlusion ⓘ metastatic colorectal cancer ⓘ myopic choroidal neovascularization ⓘ neovascular age-related macular degeneration ⓘ wet age-related macular degeneration ⓘ |
| legalStatus | prescription only ⓘ |
| mechanismOfAction |
binds VEGF-A
ⓘ
binds VEGF-B ⓘ binds placental growth factor ⓘ inhibits pathological angiogenesis ⓘ prevents VEGF interaction with its receptors ⓘ reduces vascular permeability ⓘ |
| molecularType | fusion protein of VEGF receptor domains and IgG1 Fc ⓘ |
| pregnancyCategory | may cause fetal harm (based on mechanism and animal data) ⓘ |
| regulatoryStatus |
EMA approved
ⓘ
FDA approved ⓘ |
| routeOfAdministration |
intravenous infusion
ⓘ
intravitreal injection ⓘ |
| seriousAdverseEffect |
endophthalmitis
ⓘ
retinal detachment ⓘ |
| targets |
PlGF
ⓘ
vascular endothelial growth factor A ⓘ
surface form:
VEGF-A
VEGF-B ⓘ placental growth factor ⓘ vascular endothelial growth factor A ⓘ |
| therapeuticArea |
oncology
ⓘ
ophthalmology ⓘ |
| usedWith |
FOLFIRI regimen
ⓘ
fluorouracil ⓘ folinic acid ⓘ irinotecan ⓘ |
| yearOfFirstApproval |
2011 (ophthalmic indication, United States)
ⓘ
2012 (oncology indication, United States) ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: aflibercept Description of subject: Aflibercept is an anti-VEGF biologic drug used primarily to treat neovascular (wet) age-related macular degeneration and other retinal vascular diseases.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.